Subscribe
Be the first with the news that moves the market- Units will be priced at $0.40 for gross proceeds of up to $2,610,000
- Research Capital Corporation will act as sole agent and bookrunner
- BetterLife has granted the agent an over-allotment option to increase the size of the offering by up to 15 per cent
- The offering is expected to close on or about June 7, 2021, and is pending CSE approval
- BetterLife Pharma Inc. is an emerging biotechnology company engaged in the development of psychedelic products for the treatment of mental disorders
- BetterLife Pharma Inc. is up 1.33 per cent, trading at C$0.38 per share at 4:30 pm ET
BetterLife Pharma (BETR) has announced a marketed public offering of units.
Units will be priced at $0.40 for gross proceeds of up to $2,610,000.
Research Capital Corporation will act as sole agent and bookrunner.
BetterLife has granted the agent an over-allotment option to increase the size of the offering by up to 15 per cent, exercisable at any time and from time to time up to 30 days following the closing of the offering.
Proceeds from the offering will be used for working capital and general corporate purposes.
The offering is expected to close on or about June 7, 2021, and is subject to all necessary regulatory approvals, including the approval of the Canadian Securities Exchange
BetterLife Pharma Inc. is an emerging biotechnology company engaged in the development and commercialization of next-generation psychedelic products for the treatment of mental disorders.
BetterLife Pharma Inc. is up 1.33 per cent, trading at C$0.38 per share at 4:30 pm ET.
